 |
|
|
| |
Sofosbuvir/Velpatasvir for 12 Weeks in Patients
Coinfected With HCV and HIV-1: The ASTRAL-5 Study
|
| |
| |
Reported by Jules Levin
Durban 2016 July 18-22
Norbert Brau1,2, David Wyles3, Shyam Kottilil4, Eric Daar5, Kimberly Workowski6, Annie Luetkemeyer7, Oluwatoyin Adeyemi8, Peter Ruane9, Tom McClean10, Matt Guion10,Brian Doehle10, K.C. Huang10, Anu Osinusi10, John McNally10, Diana M. Brainard10, John G. McHutchison10, Susanna Naggie11, Mark Sulkowski12
1James J. Peters Veteran Affairs Medical Center, Bronx, New York, USA; 2Icahn School of Medicine at Mount Sinai, New York, New York, USA; 3Division of Infectious Diseases, University of California, San Diego, California, USA; 4Institute of Human Virology, University of Maryland, Baltimore, Maryland, USA; 5David Geffen School of Medicine, University of California, Los Angeles, California, USA; 6Emory University, Atlanta, Georgia, USA; 7University of California, San Francisco, California, USA; 8Rush University Medical Center, Chicago, Illinois, USA; 9Ruane Medical and Liver Health Institute, Los Angeles, California, USA; 10Gilead Sciences, Inc., Foster City, California, USA; 11Duke University, Durham, North Carolina, USA; 12Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
|
| |
|
|
|
|
|
